Polarization of tumor-associated macrophage phenotype <i>via</i> porous hollow iron nanoparticles for tumor immunotherapy <i>in vivo</i>

Li, Ké; Lu, Lu; Xue, Chencheng; Liu, Ju; He, Ye; Zhou, Jun; Xia, Zengzilu; Dai, Liangliang; Luo, Zhong; Mao, Yulan; Cai, Kaiyong

doi:10.1039/c9nr06505a

Cited by 92 publications

(67 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of these lectin receptors are expressed at high levels in certain APCs, such as the C-type lectin receptors lymphocyte antigen 75 (also known as DEC-205) and C-type lectin domain family 9 member A (CLEC9A), which can be used to target dendritic cells 237 . Mannose is commonly used to target macrophages and tumour-associated macrophages [238][239][240] , but can target dendritic cells as well 241 . Particles coated with galactose, dextran or sialoadhesin can deliver to macrophages 198,240,242 .…”

Section: Nps For Immunotherapymentioning

confidence: 99%

Engineering precision nanoparticles for drug delivery

Mitchell

Billingsley

Haley

et al. 2020

Nat Rev Drug Discov

4,092

2,814

View full text Add to dashboard Cite

In recent years, the development of nanoparticles has expanded into a broad range of clinical applications. Nanoparticles have been developed to overcome the limitations of free therapeutics and navigate biological barriers — systemic, microenvironmental and cellular — that are heterogeneous across patient populations and diseases. Overcoming this patient heterogeneity has also been accomplished through precision therapeutics, in which personalized interventions have enhanced therapeutic efficacy. However, nanoparticle development continues to focus on optimizing delivery platforms with a one-size-fits-all solution. As lipid-based, polymeric and inorganic nanoparticles are engineered in increasingly specified ways, they can begin to be optimized for drug delivery in a more personalized manner, entering the era of precision medicine. In this Review, we discuss advanced nanoparticle designs utilized in both non-personalized and precision applications that could be applied to improve precision therapies. We focus on advances in nanoparticle design that overcome heterogeneous barriers to delivery, arguing that intelligent nanoparticle design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall.

show abstract

Section: Nps For Immunotherapymentioning

confidence: 99%

Engineering precision nanoparticles for drug delivery

Mitchell

Billingsley

Haley

et al. 2020

Nat Rev Drug Discov

4,092

2,814

View full text Add to dashboard Cite

show abstract

“…Recently developed nanoparticle-based therapies provide potential platforms for tumor therapy advancement [ 168 , 169 ]. The use of nanoparticles loaded with specific intracellular-signaling molecular inhibitors, such as PI 3-kinase γ inhibitor [ 170 ], to change the TAM phenotype could be a promising alternative for the direct targeting of TAM therapy in OS.…”

Section: Future Perspectivesmentioning

confidence: 99%

Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy

Cersosimo

Lonardi

Bernardini

et al. 2020

IJMS

156

116

View full text Add to dashboard Cite

Osteosarcomas (OSs) are bone tumors most commonly found in pediatric and adolescent patients characterized by high risk of metastatic progression and recurrence after therapy. Effective therapeutic management of this disease still remains elusive as evidenced by poor patient survival rates. To achieve a more effective therapeutic management regimen, and hence patient survival, there is a need to identify more focused targeted therapies for OSs treatment in the clinical setting. The role of the OS tumor stroma microenvironment plays a significant part in the development and dissemination of this disease. Important components, and hence potential targets for treatment, are the tumor-infiltrating macrophages that are known to orchestrate many aspects of OS stromal signaling and disease progression. In particular, increased infiltration of M2-like tumor-associated macrophages (TAMs) has been associated with OS metastasis and poor patient prognosis despite currently used aggressive therapies regimens. This review aims to provide a summary update of current macrophage-centered knowledge and to discuss the possible roles that macrophages play in the process of OS metastasis development focusing on the potential influence of stromal cross-talk signaling between TAMs, cancer-stem cells and additional OSs tumoral microenvironment factors.

show abstract

“…This combination of PHNP and mannosylated 3-MA synergistically activates the inflammatory factor NF-kappa B p65 of macrophages as well as helped in switching TAMs to M1-type macrophages (M1 is pro-inflammatory in nature). This resulted in activation of immune response ad inhibition of tumor growth in vivo [228].…”

Section: Immunotherapymentioning

confidence: 99%

Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies

Medina

Oza

Sharma

et al. 2020

IJERPH

212

164

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) cells are deficient in estrogen, progesterone and ERBB2 receptor expression, presenting a particularly challenging therapeutic target due to their highly invasive nature and relatively low response to therapeutics. There is an absence of specific treatment strategies for this tumor subgroup, and hence TNBC is managed with conventional therapeutics, often leading to systemic relapse. In terms of histology and transcription profile these cancers have similarities to BRCA-1-linked breast cancers, and it is hypothesized that BRCA1 pathway is non-functional in this type of breast cancer. In this review article, we discuss the different receptors expressed by TNBC as well as the diversity of different signaling pathways targeted by TNBC therapeutics, for example, Notch, Hedgehog, Wnt/b-Catenin as well as TGF-beta signaling pathways. Additionally, many epidermal growth factor receptor (EGFR), poly (ADP-ribose) polymerase (PARP) and mammalian target of rapamycin (mTOR) inhibitors effectively inhibit the TNBCs, but they face challenges of either resistance to drugs or relapse. The resistance of TNBC to conventional therapeutic agents has helped in the advancement of advanced TNBC therapeutic approaches including hyperthermia, photodynamic therapy, as well as nanomedicine-based targeted therapeutics of drugs, miRNA, siRNA, and aptamers, which will also be discussed. Artificial intelligence is another tool that is presented to enhance the diagnosis of TNBC.

show abstract

Polarization of tumor-associated macrophage phenotype via porous hollow iron nanoparticles for tumor immunotherapy in vivo

Abstract: PHNPs and 3-MA re-polarize TAMs to M1-type by activating the protein of NF-κB p65 and then remodelling the immunosuppressive microenvironment, thus activating immune response and inhibiting tumor growth.

Cited by 92 publications

References 48 publications

Engineering precision nanoparticles for drug delivery

Engineering precision nanoparticles for drug delivery

Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy

Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies

Contact Info

Product

Resources

About